Skip to main content
TipRanks
Go Ultimate75% OFF

NanoCarrier Co., Ltd. (4571) AI Stock Analysis

2 Followers
JP:4571

NanoCarrier Co., Ltd.

(TSE/TYO:4571)

Select Model
Rating:37Underperform
Price Target:JPY 64.00â–¼(-9.86% Downside)
Action:reiterated
Date:11/07/26

NanoCarrier scores at the bottom of the range, driven primarily by very weak financials: continuous losses, negative operating and free cash flow, an equity base that has halved in five years, and rising debt that signals dependence on further capital raises. Technicals reinforce the caution, with the share price well below all key moving averages and a deeply negative MACD confirming a persistent downtrend. Valuation provides no cushion, as earnings are negative and no dividend is paid. The only mitigating factors are improving loss and cash-burn trends plus a projected ~50% FY2026 revenue rebound, making this a high-risk, speculative holding whose outcome hinges on pipeline success rather than current financial performance.

Positive Factors
Revenue reboundThe sharp 2026 revenue rebound indicates that demand and commercial activity can recover after prior declines. If this improvement persists, a larger revenue base could provide operating leverage, support continued development of the DDS platform, and improve the company’s ability to fund future growth.
Negative Factors
Persistent unprofitabilityPersistent and very deep losses show that the business model has not yet reached sustainable profitability despite the recent revenue recovery. Continued losses can consume equity, restrict strategic flexibility, and make future progress dependent on successful commercialization or additional funding.

NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:4571-50.69%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.37B
Dividend Yield
―
Average Volume (3M)
710.50K
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.96
Revenue Growth
48.92%
EPS Growth
-46.91%
Country
Japan
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 P...

NanoCarrier Co., Ltd. Financial Statement Overview

Summary

Very weak fundamentals. The income statement (15) shows persistent losses, multi-year revenue decline to ¥109M in FY2025 and deeply negative net margins, despite a projected ~50% revenue rebound to ¥174M and narrowing EBIT losses in FY2026. The balance sheet (35) is eroding: equity has fallen from ¥7.5B to a projected ¥3.6B, total assets have contracted, and debt has risen to ¥1.6B (D/E 0.45), though leverage remains manageable. Cash flow (18) is the biggest concern, with negative operating and free cash flow in every period and full dependence on external financing, only partially offset by cash burn roughly halving since FY2022.

Income Statement

15Very Negative

Balance Sheet

35Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue202.50M174.50M108.52M135.51M202.19M264.03M
Gross Profit179.88M153.29M78.17M110.96M159.60M220.88M
EBITDA-1.00B-892.12M-832.57M-776.41M-1.30B-1.87B
Net Income-1.02B-943.88M-835.38M-780.00M-1.31B-1.88B
Balance Sheet
Total Assets5.24B5.91B4.00B5.07B5.78B7.14B
Cash, Cash Equivalents and Short-Term Investments4.22B4.91B3.51B4.28B4.44B5.95B
Total Debt1.20B1.60B540.24M1.11B1.11B1.15B
Total Liabilities1.92B2.34B1.26B1.65B1.53B1.57B
Stockholders Equity3.31B3.57B2.74B3.42B4.25B5.57B
Cash Flow
Free Cash Flow000-585.08M-1.09B-1.76B
Operating Cash Flow0-816.67M-401.62M-585.08M-1.09B-1.75B
Investing Cash Flow02.26B587.53M793.01M1.21B-244.13M
Financing Cash Flow02.22B-568.77M3.73M32.20M1.15B

NanoCarrier Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price71.00

Price Trends

50DMA86.54Negative
100DMA93.98Negative
200DMA118.78Negative

Market Momentum

MACD-4.97Positive
RSI39.31Neutral
STOCH25.91Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 71.00 is below the 20-day moving average (MA) of 74.90, below the 50-day MA of 86.54, and below the 200-day MA of 118.78, indicating a bearish trend. The MACD of -4.97 indicates Positive momentum. The RSI at 39.31 is Neutral, neither overbought nor oversold. The STOCH value of 25.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4571 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4588JP:458855NeutralJPY 225.09B-138.17――1748.97%35.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4583JP:458349NeutralJPY 6.14B-6.03――-13.40%7.50%
JP:4888JP:488847NeutralJPY 16.43B-15.96――-69.92%-411.54%
JP:4564JP:456445NeutralJPY 6.12B-6.52-42.81%―-25.56%17.01%
JP:4563JP:456342NeutralJPY 9.90B-1.77-558.92%―19.67%84.06%
JP:4571JP:457137UnderperformJPY 6.37B-4.46-39.57%―48.92%-46.91%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%JP:4571JP:4563JP:4564JP:4583JP:4588JP:4888Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4571 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4571NanoCarrier Co., Ltd.71.00-79.00-52.67%
JP:4563AnGes 25.00-50.00-66.67%
JP:4564OncoTherapy Science, Inc.15.00-6.00-28.57%
JP:4583Chiome Bioscience Inc.78.00-47.00-37.60%
JP:4588Oncolys BioPharma, Inc.7540.006523.00641.40%
JP:4888STELLA PHARMA CORPORATION460.00206.0081.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026